Easy, with no specific equipment needed
A urine filtration kit is made available free of charge and filters are sent at room temperature to Uromonitor Lab where the test is run and results are delivered in 5 working days.
Patients undergoing surveillance of bladder cancer, who express the need for less invasive detection methods, Uromonitor offers a totally non-invasive test that is performed in a convenient urine sample.
For the Urologists who need more accurate ancillary tests to monitor bladder cancer recurrence, Uromonitor provides an in vitro diagnosis test with a close to 100% specificity for bladder cancer and an evenly high sensitivity that is irrespective of tumor grade (unlike cytology).
A Reliable and Convenient NON-INVASIVE solution, based on a new patented urine test for FGFR3 and Tert promoter mutations, which have shown to be highly sensitive and SPECIFIC in detecting recurrence of bladder cancer.
This test can be performed adjunct to cystoscopy, reduce the associated discomfort for patients and improve their quality of life, besides reducing the economic impact of extensive surveillance.
A urine filtration kit is made available free of charge and filters are sent at room temperature to Uromonitor Lab where the test is run and results are delivered in 5 working days.
Studies in over 400 samples from eligible patients under surveillance for bladder cancer, the biomarkers have demonstrated to be highly sensitive and specific (> 97,3% sensitivity and 100% specificity).
The test is covered by an International-scope PCT Patent Application protecting the method, compositions and the probes used.
Capable of detecting from 7 abnormal molecules per 1000 normal.
Based on a simple urine analysis avoiding the recurrent cystoscopies.
The test was developed by researchers from IPATIMUP, a renowned cancer research center (www.ipatimup.pt) at Oporto, Portugal. Uromonitor’s team of researchers are experts in biomarkers in the cancer biology and molecular genetics field.
The Uromonitor test was validated with clinical samples from bladder cancer patients followed-up in international multicentre studies. A showcase study involving the leading expert in the field Dr Fred Witjes at International reference center in Urology (Radboud University Nijmegen Medical Centre – The Netherlands) has been published in 2020 (Link).
The test is performed by highly qualified personal that has been involved in performing the Uromonitor test throughout the development and validation phases, thus insuring the accumulated experience to achieve the best results. All aspects of customer relationships are handled by an expedite team of logistics and customer support experts.
State-of the art Uromonitor Lab facilities at UpTec are used to run the test, in keeping with all laboratory quality standards.
The objective of the present study was to prospectively evaluate FGFR mutation detetion in matched urine and tissue samples from patients suspicious of bladder cancer and undergoing first TURB within the framework of the BRIDGister RealWorld Experience trial. Results: The pilote cohort of the BRIDGister trial consisted of 47 patients (median age: 77, male 65% vs… Read more »
The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer. The details of… Read more »
Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with… Read more »
Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found… Read more »
Latest News / In The Press
Thursday, May 8th, 2025 We are proud to announce that the recent clinical study titled “Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer”, led by Dr. Pedro Ramos et al., has been selected as Editor’s Choice in the March 2025 edition of The Journal of Urology®. This prestigious recognition… Read more »
Thursday, February 6th, 2025 A recent systematic review and meta-analysis evaluated the performance of Uromonitor®, a urine-based biomarker test for non–muscle-invasive bladder cancer (NMIBC). Analyzing 1,190 tests across four studies, Uromonitor® achieved 80.2% sensitivity, 96.9% specificity, and a high negative predictive value (96.6%). Compared to urinary cytology, Uromonitor® significantly improved sensitivity and test accuracy, reducing unnecessary cystoscopies by up… Read more »
Thursday, February 6th, 2025 A recent clinical study has confirmed the effectiveness of Uromonitor, an innovative urinary biomarker for the surveillance of nonmuscle-invasive bladder cancer (NMIBC). In a cohort of 439 patients with 528 surveillance episodes, the study demonstrated a sensitivity of 87% and specificity of 99%, along with a negative predictive value of 99%. These results confirm Uromonitor®’s eliability… Read more »
Thursday, February 6th, 2025 Uromonitor®: Reducing Unnecessary Cystoscopies and TURBT Procedures Non-muscle-invasive bladder cancer (NMIBC) follow-up relies on frequent cystoscopies, which are invasive, costly, and uncomfortable. Uromonitor® is a non-invasive urine test that detects NMIBC recurrence with high accuracy, significantly reducing unnecessary procedures. Fewer Cystoscopies – Uromonitor® could have prevented 87.4% of unnecessary cystoscopies, reducing patient discomfort and healthcare… Read more »
Thursday, February 6th, 2025 Uromonitor-V2®: A Breakthrough in NMIBC Surveillance Bladder cancer (BCa) requires lifelong monitoring, but traditional methods like cystoscopy and urine cytology are invasive, costly, and often lack sensitivity. Uromonitor-V2® is a non-invasive urine test that detects TERT, FGFR3, and KRAS mutations using real-time qPCR. Clinically validated, it outperforms urine cytology with 93.1% sensitivity and 85.4% specificity,… Read more »
Monday, December 27th, 2021 Uromonitor test was recognized and considered by the scientific community as an excellent alternative for the non-invasive follow-up of patients previously diagnosed with Non-Muscle Invasive Bladder Cancer in a scientific article that was issue cover in an recognized international journal (Diagnostics). The details of this study can be found at: https://www.mdpi.com/2075-4418/10/1/39/htm
Monday, December 27th, 2021 Concerned about the postponement of surveillance procedures and the increased risk of contamination in Hospitals, a team of researchers from Ipatimup and the Institute for Research and Innovation in Health (i3S) validated a new form of bladder cancer surveillance that, from now on, may be carried-out from home. Bladder cancer mainly affects smoking men over… Read more »
Wednesday, February 5th, 2020 The Uromonitor test was recently validated by the scientific community in a international recognized peer-reviewed journal (Frontiers in Genetics) in a multicentric study comprising more than 300 human samples. Uromonitor presented high sensitivity (74%) and specificity (93%) in the detection of recurrence in patients under Follow-up for Non-Muscle Invasive Bladder Cancer. The details of this… Read more »
Wednesday, February 5th, 2020 Recently, investigators described in a scientific publications in a recognized international journal (International Journal of Molecular Sciences), the future possibility of the use of an genetic alterations in TERT gene, included in the Uromonitor test, to be used as a therapy response predictive biomarker in BCG treatment. The details of this study can be found… Read more »
The test is currently performed as a service at Uromonitor, hosted at the above mentioned institutions.
To access the service, urologists in hospitals and clinics should first have materials for urine collection and shipment.
Direct ordering the complete analysis kit to be performed in a laboratory or medical unit.
Recommended for professionals!
“For persons at risk or patients diagnosed with bladder cancer, as well as their urologist, who have the need of more convenient surveillance methods, Uromonitor is a completely non-invasive, urine-based, In vitro Diagnosis (IVD) kit that is able to detect bladder cancer with high sensitivity and specificity.
Uromonitor is easy and can deliver reliable results to reduce costs with follow-up”.
